Potential therapeutic role of natural killer cells in cancer

Bibliography

• COOPER MA, FEHNIGER TA, FUCHS A, COLONNA M, CALIGIURI MA: NK cell and DC interations. Trends Immunol. (2004) 25(1):47-52.
   PubMed Web of Science ®Google Scholar
• CUDKOWICZ G, BENNETT M: Peculiar immunobiology of bone marrow allografts: I. graft rejection by irradiated responder mice. J. Exp. Med. (1971) 134:83-102.
   PubMed Web of Science ®Google Scholar
• MURPHY WJ, KOH CY, RAZIUDDIN A, BENNETT M, LONGO DL: Immunobiology of natural killer cells and bone marrow transplantation: merging basic and preclinical studies. Immunol. Rev. (2001) 181(1):279-289.
   PubMed Web of Science ®Google Scholar
• KIESSLING R, KLEIN E, WIGZELL H: ‘Natural’ killer cells in the mouse. I. cytotoxic cells with specificity for mouse moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. (1975) 5:112-117.
   PubMed Web of Science ®Google Scholar
• MORETTA A, BOTTINO C, MINGARI MC, BIASSONI R, MORETTA L: What is a natural killer cell? Nat. Immunol. (2002) 3(1):6-8.
   PubMed Web of Science ®Google Scholar
• ANDRE P, SPERTINI O, GUIA S et al.: Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin. Proc. Natl. Acad. Sci. USA (2000) 97(7):3400-3405.
   PubMed Web of Science ®Google Scholar
• MILLER JS: The biology of natural killer cells in cancer, infection, and pregnancy. Exp. Hematol. (2001) 29(10):1157-1168.
   PubMed Web of Science ®Google Scholar
• COOPER MA, FEHNIGER TA, CALIGIURI MA: The biology of human natural killer-cell subsets. Trends Immunol. (2001) 22(11):633-640.
   PubMed Web of Science ®Google Scholar
• FARAG S, CALIGIURI M: Human natural killer cell development and biology. Blood Rev. (2006) 20(3):123-137.
   PubMed Web of Science ®Google Scholar
• FEHNIGER TA: Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. (2002) 13(2):169-183.
   PubMed Web of Science ®Google Scholar
• TROTTA R, PARIHAR R, YU J et al.: Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood (2005) 105(8):3011-3018.
   PubMed Web of Science ®Google Scholar
• ROBERTSON MJ, MANLEY TJ, DONAHUE C, LEVINE H, RITZ J: Costimulatory signals are required for optimal proliferation of human natural killer cells. J. Immunol. (1993) 150(5):1705-1714.
   PubMed Web of Science ®Google Scholar
• MILLER JS: Biology of natural killer cells in cancer and infection. Cancer Invest. (2002) 20(3):405-419.
   PubMed Web of Science ®Google Scholar
• COUDERT JD, HELD W: The role of the NKG2D receptor for tumor immunity. Semin. Cancer Biol. (2006) 16(5):333-343.
   PubMed Web of Science ®Google Scholar
• GUMA M, BUSCH LK, SALAZAR-FONTANA LI: The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells. Eur. J. Immunol. (2005) 35(7):2071-2080.
   PubMed Web of Science ®Google Scholar
• SEINO K, MOTOHASHI S, FUJISAWA T, NAKAYAMA T, TANIGUCHI M: Natural killer T cell-mediated anti-tumor immune responses and their clinical applications. Cancer Sci. (2006) 9(9):807-812.
   Google Scholar
• TANAKA J, ASAKA M, IMAMURA M: Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia. Int. J. Hematol. (2005) 81(1):6-12.
   PubMed Web of Science ®Google Scholar
• GALY A, TRAVIS M, CEN D, CHEN B: Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity (1995) 3(4):459-473.
   PubMed Web of Science ®Google Scholar
• COLUCCI F, CALIGIURI MA, DI SANTO JP: What does it take to make a natural killer? Nat. Rev. Immunol. (2003) 3(5):413-425.
   PubMed Web of Science ®Google Scholar
• SIVAKUMAR PV, FOSTER DC, CLEGG CH: Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumor responses. Immunology (2004) 112(2):177-182.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA WM, KIM S, FRENCH AR: The dynamic life of natural killer cells. Annu. Rev. Immunol. (2004) 22:405-429.
   PubMed Web of Science ®Google Scholar
• FREUD AG, YOKOHAMA A, BECKNELL B et al.: Evidence for discrete stages of human natural killer cell differentiation in vivo. J. Exp. Med. (2006) 203(4):1033-1043.
   PubMed Web of Science ®Google Scholar
• FREUD AG, BECKNELL B, ROYCHOWDHURY S et al.: A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity (2005) 22(3):295-304.
   PubMed Web of Science ®Google Scholar
• LOZA MJ, PERUSSIA B: The IL-12 signature: NK cell terminal CD56+high stage and effector functions. J. Immunol. (2004) 172(1):88-96.
   PubMed Web of Science ®Google Scholar
• DURIG JD, GIESE A, SCHULZ-SCHAEFFER W et al.: Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. Br. J. Haematol. (2000) 108(3):488-495.
   PubMed Web of Science ®Google Scholar
• FEHNIGER TA, COOPER MA, NUOVO GJ et al.: CD56bright natural killer cells are present in human lymph nodes and are activated by T cell–derived IL-2: a potential new link between adaptive and innate immunity. Blood (2003) 101(8):3052-3057.
   PubMed Web of Science ®Google Scholar
• JOHANSSON S, HALL H, BERG L, HOGLUND P: NK cells in autoimmune disease. Curr. Top. Microbiol. Immunol. (2006) 298:259-277.
   PubMed Web of Science ®Google Scholar
• MORETTA A, MARCENARO E, SIVORI S, DELLA CHIESA M, VITALE M, MORETTA L: Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. (2005) 26(12):668-675.
   PubMed Web of Science ®Google Scholar
• O’LEARY JG, GOODARZI M, DRAYTON DL, VON ANDRIAN UH: T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat. Immunol. (2006) 7(5):507-516.
   PubMed Web of Science ®Google Scholar
• FERLAZZO G, MUNZ C: NK cell compartments and their activation by dendritic cells. J. Immunol. (2004) 172(3):1333-1339.
   PubMed Web of Science ®Google Scholar
• WALLACE ME, SMYTH MJ: The role of natural killer cells in tumor control – effectors and regulators of adaptive immunity. Springer Semin. Immunopathol. (2005) 27(1):49-64.
   PubMed Web of Science ®Google Scholar
• LI Q, KAWADA T: The mechanism of organophosphorus pesticide-induced inhibition of cytolytic activity of killer cells. Cell. Mol. Immunol. (2006) 3(3):171-178.
   PubMed Web of Science ®Google Scholar
• SMYTH MJ, CRETNEY E, KELLY JM et al.: Activation of NK cell cytotoxicity. Mol. Immunol. (2005) 42(4):501-510.
   PubMed Web of Science ®Google Scholar
• MORETTA L, BOTTINO C, PENDE D, CASTRICONI R, MINGARI MC, MORETTA A: Surface NK receptors and their ligands on tumor cells. Semin. Immunol. (2006) 18(3):151-158.
   PubMed Web of Science ®Google Scholar
• MALMBERG KJ: Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol. Immunother. (2004) 53(10):879-892.
   PubMed Web of Science ®Google Scholar
• PORGADOR A, MANDELBOIM O, RESTIFO NP, STROMINGER JL: Natural killer cell lines kill autologous b2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA (1997) 94(24):13140-13145.
   PubMed Web of Science ®Google Scholar
• HOFMEISTER V, WEISS EH: HLA-G modulates immune responses by diverse receptor interactions. Semin. Cancer Biol. (2003) 13(5):317-323.
   PubMed Web of Science ®Google Scholar
• MASON LH, GOSSELIN P, ANDERSON SK, FOGLER WE, ORTALDO JR, MCVICAR DW: Differential tyrosine phosphorylation of inhibitory versus activating Ly-49 receptor proteins and their recruitment of SHP-1 phosphatase. J. Immunol. (1997) 159(9):4187-4196.
   PubMed Web of Science ®Google Scholar
• WANG JW, HOWSON JM, GHANSAH T et al.: Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science (2002) 295(5562):2094-2097.
   PubMed Web of Science ®Google Scholar
• RE F, STAUDACHER C, ZAMAI L, VECCHIO V, BREGNI M: Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer (2006) 107(3):640-648.
   PubMed Web of Science ®Google Scholar
• PARHAM P: MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. (2005) 5(3):201-214.
   PubMed Web of Science ®Google Scholar
• BIASSONI R, CANTONI C, MARRAS D et al.: Human natural killer cell receptors: insights into their molecular function and structure. J. Cell. Mol. Med. (2003) 7(4):376-387.
   PubMed Web of Science ®Google Scholar
• VIVIER E: What is natural in natural killer cells? Immunol. Lett. (2006) 107(1):1-7.
   PubMed Web of Science ®Google Scholar
• VALIANTE NM, MARKUS U, SHILLING HG et al.: Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity (1997) 7(6):739-751.
   PubMed Web of Science ®Google Scholar
• KUSUMI M, YAMASHITA T, FUJII T, NAGAMATSU T, KOZUMA S, TAKETANI Y: Expression patterns of lectin-like natural killer receptors, inhibitory CD94/NKG2A, and activating CD94/NKG2C on decidual CD56bright natural killer cells differ from those on peripheral CD56dim natural killer cells. J. Reprod. Immunol. (2006) 70(1-2):33-42.
   PubMed Web of Science ®Google Scholar
• RAJAGOPALAN S, LONG EO: Understanding how combinations of HLA and KIR genes influence disease. J. Exp. Med. (2005) 201(7):1025-1029.
   PubMed Web of Science ®Google Scholar
• SZE DY, BROWN R, YANG S, HO PJ, GIBSON J, JOSHUA D: The use of thalidomide in myeloma therapy as an effective anticancer drug. Curr. Cancer Drug Targets (2006) 6(4):325-331.
   PubMed Web of Science ®Google Scholar
• SARANGI I, GHOSH D, BHUTIA SK, MALLICK SK, MAITI TK: Anti-tumor and immunomodulating effects of pleurotus ostreatus mycelia-derived proteoglycans. Int. Immunopharmacol. (2006) 6(8):1287-1297.
   PubMed Web of Science ®Google Scholar
• ZITVOGEL L, TESNIERE A, KROEMER G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. (2006) 6(10):715-727.
   PubMed Web of Science ®Google Scholar
• JACKSON AL, LOEB LA: The mutation rate and cancer. Genetics (1998) 148(4):1483-1490.
   PubMed Web of Science ®Google Scholar
• KHONG HT, RESTIFO NP: Natural selection of tumor variants in the generation of ‘tumor escape’ phenotypes. Nat. Immunol. (2002) 3(11):999-1005.
   PubMed Web of Science ®Google Scholar
• AHMAD M, RC REES, SA ALI: Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. (2004) 53(10):844-854.
   PubMed Web of Science ®Google Scholar
• HAYAKAWA Y, SMYTH MJ: Innate immune recognition and suppression of tumors. Adv. Cancer Res. (2006) 95:293-322.
   PubMed Web of Science ®Google Scholar
• WATSON NF, SPENDLOVE I, MADJD Z et al.: Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int. J. Cancer (2006) 118(6):1445-1452.
   PubMed Web of Science ®Google Scholar
• GROH V, WU J, YEE C, SPIES T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 419(6908):734-738.
   PubMed Web of Science ®Google Scholar
• ALGARRA I, GARCIA-LORA A, CABRERA T, RUIZ-CABELLO F, GARRIDO F: The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. (2004) 53(10):904-910.
   PubMed Web of Science ®Google Scholar
• OPPENHEIM DE, ROBERTS SJ, CLARKE SL, FILLER R et al.: Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. (2005) 6(9):928-937.
   PubMed Web of Science ®Google Scholar
• ALTER G, SUSCOVICH TJ, KLEYMAN M et al.: Low perforin and elevated SHIP-1 expression is associated with functional anergy of natural killer cells in chronic HIV-1 infection. AIDS (2006) 20(11):1549-1551.
   PubMed Web of Science ®Google Scholar
• COOLEY S, MCCULLAR V, WANGEN R et al.: KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood (2005) 106(13):4370-4376.
   PubMed Web of Science ®Google Scholar
• MILLER AM, LUNDBERG K, OZENCI V et al.: CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. (2006) 177(10):7398-7405.
   PubMed Web of Science ®Google Scholar
• SULLIVAN KE, DELAAT CA, DOUGLAS SD, FILIPOVICH: Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr. Res. (1998) 44(4):465-468.
   PubMed Web of Science ®Google Scholar
• PASSWEG JR, STERN M, KOEHL U, UHAREK L, TICHELLI A: Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant. (2005) 35(7):637-643.
   PubMed Web of Science ®Google Scholar
• RUGGERI L, CAPANNI M, URBANI E et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295(5562):2097-2100.
   PubMed Web of Science ®Google Scholar
• WITT CS, CHRISTIANSEN FT: The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang. (2006) 90(1):10-20.
   PubMed Web of Science ®Google Scholar
• BISHARA A, DE SANTIS D, WITT CC et al.: The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens (2004) 63(3):204-211.
   PubMed Web of Science ®Google Scholar
• JOHNSON BD, TRUITT RL: A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. Transplantation (1992) 54(1):104-112.
   PubMed Web of Science ®Google Scholar
• LEFKOWITZ M, JORKASKY D, KORNBLUTH J: Increase in natural killer activity in cyclosporine-treated renal allograft recipients during rejection. Hum. Immunol. (1987) 19(2):139-149.
   PubMed Web of Science ®Google Scholar
• ROONY CM, WIMPERIS JZ, BRENNER MK, PATTERSON J, HOFFBRAND AV, PRENTICE HG: Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br. J. Haematol. (1986) 62(3):413-420.
   PubMed Web of Science ®Google Scholar
• RUGGERI L, CAPANNI M, TOSTI A et al.: Innate immunity against hematological malignancies. Cytotherapy (2002) 4(4):343-346.
   PubMed Web of Science ®Google Scholar
• MILLER JS, SOIGNIER Y, PANOSKALTSIS A et al.: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105(8):3051-3057.
   PubMed Web of Science ®Google Scholar
• RUGGERI L, MANCUSI A, CAPANNI M, MARTELLI MF, VELARDI A: Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr. Opin. Immunol. (2005) 17(2):211-217.
   PubMed Web of Science ®Google Scholar
• PARHAM P, MCQUEEN KL: Alloreactive killer cells: hindrance and help for hematopoietic transplants. Nat. Rev. Immunol. (2003) 3(2):108-122.
   PubMed Web of Science ®Google Scholar
• KOH CY, WELNIAK LA, MURPHY WJ: Adoptive cellular immunotherapy: NK cells and bone marrow transplantation. Histol. Histopathol. (2000) 15(4):1201-1210.
   PubMed Web of Science ®Google Scholar
• VAN ROOD JJ: Immunogenetics. Curr. Opin. Hematol. (1994) 1(6):429-434.
   PubMedGoogle Scholar
• SHILLING HG, MCQUEEN KL, CHENG NW, SHIZURU JA, NEGRIN RS, PARHAM P: Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood (2003) 101(9):3730-3740.
   PubMed Web of Science ®Google Scholar
• REDDY V, LEVINE JB, MAHMOOD SS, SCHOLD JD, MEIER-KRIESCH H, DUNBAR EM: Natural killer (NK) cells are associated with reduced relapse without increasing graft-versus-host disease (GVHD) after allogeneic hematopoetic stem-cell transplantation (HSCT). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2006) 24(18S):Abstract 6542.
   Google Scholar
• REDDY V, ITURRASPE JA, TZOLAS AC, MEIER-KRIESHE HU, SCHOLD J, WINGARD JR: Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood (2004) 103(11):4330-4335.
   PubMed Web of Science ®Google Scholar
• REDDY V, WINER AG, EKSIOGLU E, MEIER-KRIESCHE HU, SCHOLD JD, WINGARD JR: Interleukin-12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. (2005) 11(12):1014-1021.
   PubMed Web of Science ®Google Scholar
• WALZER T, DALOD M, ROBBINS SH, ZITVOGEL L, VIVIER E: Natural-killer cells and dendritic cells: ‘l’union fait la force.’ Blood (2005) 106(7):2252-2258.
   PubMed Web of Science ®Google Scholar
• MARTI F, PARDO N, PEIRO M et al.: Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Exp. Hematol. (1995) 23(14):1445-1452.
   PubMed Web of Science ®Google Scholar
• KALWAK K, USSOWICZ M, GORCZYNSKA E et al.: Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors. J. Interferon Cytokine Res. (2003) 23(4):173-181.
   PubMed Web of Science ®Google Scholar
• CLEMENCEAU B, GALLOT G, VIVIEN R et al.: Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. J. Immunother. (2006) 29(1):53-60.
   PubMed Web of Science ®Google Scholar
• COOLEY S, BURNS LJ, REPKA T, MILLER JS: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp. Hematol. (1999) 27(10):1533-1541.
   PubMed Web of Science ®Google Scholar
• ZHANG T, AMMORETTE B, SENTMAN CL: Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. (2006) 66(11):5917-5933.
   Google Scholar
• TONN T, BECKER S, ESSER R, SCHWABE D, SEIFRIED E: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J. Hematother. Stem Cell Res. (2001) 10(4):535-544.
   PubMed Web of Science ®Google Scholar
• ARAI S, KINDY K, SWEARINGEN M Phase I study of adoptive immunotherapy using the cytotoxic natural killer (NK) cell line, NK-92, for treatment of advanced renal cell carcinoma and malignant melanoma. Blood (2003) 102(11):Abstract 2566.
   Google Scholar
• KRAUSE SW, GASTPAR R, ANDREESEN R et al.: Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical Phase I trial. Clin. Cancer Res. (2004) 10(11):3699-3707.
   PubMed Web of Science ®Google Scholar
• BURNS LJ, WEISDORF DJ, DEFOR TE: IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a Phase I/II trial. Bone Marrow Transplant. (2003) 32(2):177-86
   PubMed Web of Science ®Google Scholar
• LEEMHUIS T, WELLS S, SCHEFFOLD C: A Phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. (2005) 11(3):181-187.
   PubMed Web of Science ®Google Scholar
• STRAIR RK, SCHAAR D, MEDINA D et al.: Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. Am. J. Clin. Oncol. (2003) 21(20):3785-3791.
   PubMed Web of Science ®Google Scholar
• CLEMENCEAU B, GALLOT G, VIVIEN R, GASCHET J, CAMPONE M, VIE H: Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. J. Immunother. (2006) 29(1):53-60.
   PubMed Web of Science ®Google Scholar
• IGARASHI T, WYNBERG J, SRINIVASAN R et al.: Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood (2004) 104(1):170-177.
   PubMed Web of Science ®Google Scholar
• LUHM J, BRAND JM, KORITKE P, HOPPNER M, KIRCHNER H, FROHN C: Large-scale generation of natural killer lymphocytes for clinical application. J. Hematother. Stem Cell Res. (2002) 11(4):651-657.
   PubMedGoogle Scholar
• KOEHL U, ESSER R, ZIMMERMANN S, TONN T: Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin. Padiatr. (2005) 217(6):345-350.
   PubMed Web of Science ®Google Scholar
• SUCK G: Novel approaches using natural killer cells in cancer therapy. Semin. Cancer Biol. (2006) 16(5):412-418.
   PubMed Web of Science ®Google Scholar
• TAM YK, MARTINSON JA, DOLIGOSA K, KLINGEMANN H-G: Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy (2003) 5(3):259-272.
   PubMed Web of Science ®Google Scholar
• KLINGEMANN H-G: Natural killer cell-based immunotherapeutic strategies. Cytotherapy (2005) 7(1):16-22.
   PubMed Web of Science ®Google Scholar
• SENTMAN CL, BARBER MA, BARBER A, ZHANG T: NK cell receptors as tools in cancer immunotherapy. Adv. Cancer Res. (2006) 95:249-292.
   PubMed Web of Science ®Google Scholar
• SHERIDAN C: First-in-class cancer therapeutic to stimulate natural killer cells. Nat. Biotechnol. (2006) 24(6):597.
   PubMed Web of Science ®Google Scholar
• UHAREK L, GLASS B, GASKA T et al.: Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model. Bone Marrow Transplant. (1993) 12(0):S57-S60.
   PubMed Web of Science ®Google Scholar
• MEROPOL NJ, BARRESI GM, FEHNIGER TA, HITT J, FRANKLIN M, CALIGIURI MA: Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother. (1998) 46(6):318-326.
   PubMed Web of Science ®Google Scholar
• WATFORD WT, MORIQUCHI M, MORINOBU A, O’SHEA JJ: The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. (2003) 14(5):361-368.
   PubMed Web of Science ®Google Scholar
• JIA SF, DUAN X, WORTH LL et al.: Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing’s sarcoma. Cancer Gene Ther. (2006) 13(10):948-957.
   PubMed Web of Science ®Google Scholar
• LAU AS, SIGAROUDINIA M, YEUNG MC, KOHL S: Interleukin-12 induces interferon-gamma expression and natural killer cytotoxicity in cord blood mononuclear cells. Pediatr. Res. (1996) 39(1):150-155.
   PubMedGoogle Scholar
• POATY-MAVOUNGOU V, TOURE FS, TEVI-BENISSAN C, MAVOUNGOU E: Enhancement of natural killer cell activation and antibody-dependent cellular cytotoxicity by interferon-alpha and interleukin-12 in vaginal mucosae Sivmac251-infected Macaca fascicularis. Viral Immunol. (2002) 15(1):197-212.
   PubMed Web of Science ®Google Scholar
• U’REN L, KEDL R, DOW S: Vaccination with liposome-DNA complexes elicits enhanced antitumor immunity. Cancer Gene Ther. (2006) 13(11):1033-1044.
   PubMed Web of Science ®Google Scholar
• STEIN MN, SHIN J, GUDZOWATY O, BERNSTEIN AM, LIU JM: Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res. (2006) 26:1759-1763.
   PubMed Web of Science ®Google Scholar